Identification

Name
Glipizide
Accession Number
DB01067  (APRD00436)
Type
Small Molecule
Groups
Approved, Investigational
Description

An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.

Structure
Thumb
Synonyms
  • 1-cyclohexyl-3-({p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl}sulfonyl)urea
  • Glipizida
  • Glipizide
  • Glipizidum
  • N-{4-[β-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulphonyl}-N'-cyclohexylurea
External IDs
CP 28,720 / CP 28720 / CP-28,720 / CP-28720 / K 4024 / K-4024
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GlipizideTablet, extended release5 mg/1OralRemedy Repack2011-12-082016-12-14Us
Glipizide ERTablet, extended release10 mg/1OralCardinal Health1994-04-262018-07-10Us
Glipizide XLTablet, extended release5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Glipizide XLTablet, extended release2.5 mg/1OralCardinal Health1994-04-26Not applicableUs
Glipizide XLTablet, extended release10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs59762 5033 02 nlmimage10 8015c00e
Glipizide XLTablet, extended release2.5 mg/1OralCardinal Health1994-04-262017-12-22Us
GlucotrolTablet5 mg/1OralRoerig1984-05-08Not applicableUs
GlucotrolTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.1984-05-08Not applicableUs
GlucotrolTablet10 mg/1OralRoerig1984-05-08Not applicableUs
Glucotrol XLTablet, extended release10 mg/1OralPhysicians Total Care, Inc.1994-09-30Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GlipizideTablet5 mg/1OralNu Care Pharmaceuticals,inc.1995-02-27Not applicableUs
GlipizideTablet10 mg/1OralAidarex Pharmaceuticals LLC2002-09-25Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2013-01-032017-02-22Us00172 3649 60 nlmimage10 a126d0d6
GlipizideTablet10 mg/1OralUpsher Smith Laboratories2015-03-092017-07-31Us
GlipizideTablet10 mg/1OralA S Medication Solutions2002-09-25Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2010-11-232017-03-03Us
GlipizideTablet10 mg/1OralStat Rx USA1995-02-272018-02-08Us
GlipizideTablet5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
GlipizideTablet5 mg/1OralRemedy Repack2013-05-302017-12-30Us16729 0139 16 nlmimage10 f03b786b
GlipizideTablet10 mg/1Oralbryant ranch prepack1995-02-27Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Glipizide and Metformin HClGlipizide (2.5 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coatedOralHeritage2010-06-29Not applicableUs
Glipizide and Metformin HClGlipizide (5 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coatedOralA S Medication Solutions2010-06-292017-06-20Us
Glipizide and Metformin HClGlipizide (2.5 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coatedOralRemedy Repack2013-11-192016-12-24Us23155 0116 01 nlmimage10 bd3b5e8a
Glipizide and Metformin HClGlipizide (5 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coatedOralRemedy Repack2014-02-182017-09-09Us23155 0117 01 nlmimage10 2c461610
Glipizide and Metformin HClGlipizide (2.5 mg/1) + Metformin Hydrochloride (250 mg/1)Tablet, film coatedOralHeritage2010-06-29Not applicableUs
Glipizide and Metformin HClGlipizide (5 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coatedOralHeritage2010-06-29Not applicableUs
Glipizide and Metformin HClGlipizide (2.5 mg/1) + Metformin Hydrochloride (250 mg/1)Tablet, film coatedOralLake Erie Medical Dba Quality Care Produts Llc2010-06-292018-04-13Us
Glipizide and Metformin HydrochlorideGlipizide (5 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coatedOralA S Medication Solutions2005-10-28Not applicableUs
Glipizide and Metformin HydrochlorideGlipizide (2.5 mg/1) + Metformin Hydrochloride (500 mg/1)Tablet, film coatedOralCadila Pharnmaceuticals2016-05-05Not applicableUs
Glipizide and Metformin HydrochlorideGlipizide (2.5 mg/1) + Metformin Hydrochloride (250 mg/1)Tablet, film coatedOralWatson Pharmaceuticals2005-10-282016-04-20Us
International/Other Brands
Aldiab / Digrin / Dipazide / Glibenese (Pfizer) / Glibénèse (Dexo) / Glibetin (Johnson) / Glican / Glidiab / Glipid / Glipin (Swiss Pharm) / Glix (YSP) / Gluco-Rite / Glucolip / Glucozide / Glupitel / Glupizide / Glyde / Glydiazinamide / Melizide / Mindiab (Pfizer) / Minidab / Minidiab (Pfizer) / Minodiab / Napizide / Ozidia / Sucrazide / Zitrol XR (Square)
Categories
UNII
X7WDT95N5C
CAS number
29094-61-9
Weight
Average: 445.535
Monoisotopic: 445.178375067
Chemical Formula
C21H27N5O4S
InChI Key
ZJJXGWJIGJFDTL-UHFFFAOYSA-N
InChI
InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)
IUPAC Name
N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide
SMILES
CC1=CN=C(C=N1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1

Pharmacology

Indication

For use as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory.

Associated Conditions
Pharmacodynamics

Glipizide, a second-generation sulfonylurea, is used with diet to lower blood glucose in patients with diabetes mellitus type II. The primary mode of action of glipizide in experimental animals appears to be the stimulation of insulin secretion from the beta cells of pancreatic islet tissue and is thus dependent on functioning beta cells in the pancreatic islets. In humans glipizide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. In man, stimulation of insulin secretion by glipizide in response to a meal is undoubtedly of major importance. Fasting insulin levels are not elevated even on long-term glipizide administration, but the postprandial insulin response continues to be enhanced after at least 6 months of treatment. Some patients fail to respond initially, or gradually lose their responsiveness to sulfonylurea drugs, including glipizide.

Mechanism of action

Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.

TargetActionsOrganism
AATP-binding cassette sub-family C member 8
inhibitor
Human
UPeroxisome proliferator-activated receptor gamma
agonist
Human
Absorption

Gastrointestinal absorption is uniform, rapid, and essentially complete.

Volume of distribution
  • 11 L
Protein binding

98-99%, primarily to albumin.

Metabolism

Hepatic. The major metabolites of glipizide are products of aromatic hydroxylation and have no hypoglycemic activity. A minor metabolite which accounts for less than 2% of a dose, an acetylaminoethyl benzine derivatives, is reported to have 1/10 to 1/3 as much hypoglycemic activity as the parent compound.

Route of elimination

The primary metabolites are inactive hydroxylation products and polar conjugates and are excreted mainly in the urine.

Half life

2-5 hours

Clearance
Not Available
Toxicity

The acute oral toxicity was extremely low in all species tested (LD50 greater than 4 g/kg). Overdosage of sulfonylureas including glipizide can produce hypoglycemia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C9CYP2C9*3(C;C) / (A;C)C AlleleEffect Directly StudiedPatients with this genotype have reduced metabolism of glipizide.Details
Glucose-6-phosphate 1-dehydrogenaseVilleurbanneNot Available1000_1002delACCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTorunNot Available1006A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSunderlandNot Available105_107delCATADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIwatsukiNot Available1081G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSerresNot Available1082C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTondelaNot Available1084_1101delCTGAACGAGCGCAAGGCCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLoma LindaNot Available1089C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAachenNot Available1089C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTenriNot Available1096A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontpellierNot Available1132G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCalvo MackennaNot Available1138A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRileyNot Available1139T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOlomoucNot Available1141T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTomahNot Available1153T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLynwoodNot Available1154G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMadridNot Available1155C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIowa, Walter Reed, SpringfieldNot Available1156A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBeverly Hills, Genova, Iwate, Niigata, YamaguchiNot Available1160G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHartfordNot Available1162A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePrahaNot Available1166A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKrakowNot Available1175T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWisconsinNot Available1177C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNashville, Anaheim, PorticiNot Available1178G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAlhambraNot Available1180G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBariNot Available1187C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePuerto LimonNot Available1192G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCovao do LoboNot Available1205C>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseClinicNot Available1215G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUtrechtNot Available1225C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSuwalkiNot Available1226C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRiversideNot Available1228G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseJapan, ShinagawaNot Available1229G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKawasakiNot Available1229G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMunichNot Available1231A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGeorgiaNot Available1284C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSumareNot Available1292T->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTelti/KobeNot Available1318C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiago de Cuba, MoriokaNot Available1339G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarimaNot Available1358T->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFiguera da FozNot Available1366G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmiensNot Available1367A>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkok NoiNot Available1376G->T, 1502T->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFukayaNot Available1462G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCampinasNot Available1463G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBuenos AiresNot Available1465C>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseArakawaNot Available1466C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBrightonNot Available1488_1490delGAAADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKozukataNot Available159G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmsterdamNot Available180_182delTCTADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNo nameNot Available202G->A, 376A->G, 1264C>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSwanseaNot Available224T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUrayasuNot Available281_283delAGAADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVancouverNot Available317C->G544C->T592C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMt SinaiNot Available376A->G, 1159C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePlymouthNot Available488G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVolendamNot Available514C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseShinshuNot Available527A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChikugoNot Available535A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTsukuiNot Available561_563delCTCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePedoplis-CkaroNot Available573C>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiagoNot Available593G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMinnesota, Marion, Gastonia, LeJeuneNot Available637G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCincinnatiNot Available637G->T, 1037A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarilaouNot Available648T->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNorth DallasNot Available683_685delACAADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahikawaNot Available695G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseDurhamNot Available713A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseStonybrookNot Available724_729delGGCACTADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWayneNot Available769C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAveiroNot Available806G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCleveland CorumNot Available820G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLilleNot Available821A>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkokNot Available825G>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSugaoNot Available826C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLa JollaNot Available832T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWexhamNot Available833C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePiotrkowNot Available851T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWest VirginiaNot Available910G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOmiyaNot Available921G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaraNot Available953_976delCCACCAAAGGGTACCTGGAC GACCADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseManhattanNot Available962G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRehevotNot Available964T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHoniaraNot Available99A->G / 1360C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTokyo, FukushimaNot Available1246G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChathamNot Available1003G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFushanNot Available1004C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePartenopeNot Available1052G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIerapetraNot Available1057C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnadiaNot Available1193A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAbenoNot Available1220A->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSurabayaNot Available1291G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePawneeNot Available1316G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseS. AntiocoNot Available1342A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCassanoNot Available1347G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHermoupolisNot Available1347G->C / 1360C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUnion,Maewo, Chinese-2, KaloNot Available1360C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAndalusNot Available1361G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCosenzaNot Available1376G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCanton, Taiwan- Hakka, Gifu-like, Agrigento-likeNot Available1376G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFloresNot Available1387C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKaiping, Anant, Dhon, Sapporo-like, WoseraNot Available1388G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamogawaNot Available169C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCostanzoNot Available179T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmazoniaNot Available185C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSongklanagarindNot Available196T->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHechiNot Available202G->A / 871G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNamouruNot Available208T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBao LocNot Available352T>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCrispimNot Available375G->T, 379G->T383T->C384C>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAcrokorinthosNot Available376A->G / 463C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSanta MariaNot Available376A->G / 542A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnanindeuaNot Available376A->G / 871G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVanua LavaNot Available383T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseValladolidNot Available406C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBelemNot Available409C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLiuzhouNot Available442G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseShenzenNot Available473G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTaipei “Chinese- 3”Not Available493A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseToledoNot Available496C>TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaoneNot Available497G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNankangNot Available517T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMiaoliNot Available519C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMediterranean, Dallas, Panama‚ Sassari, Cagliari, BirminghamNot Available563C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCoimbra ShundeNot Available592C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNilgiriNot Available593G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRadlowoNot Available679C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRoubaixNot Available811G>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHaikouNot Available835A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-1Not Available835A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMizushimaNot Available848A>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOsakaNot Available853C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseViangchan, JammuNot Available871G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeoulNot Available916G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLudhianaNot Available929G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFarroupilhaNot Available977C->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-5Not Available1024C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRignanoNot Available130G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOrissaNot Available131C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseG6PDNiceNot Available1380G>CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamiube, KeelungNot Available1387C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNeapolisNot Available1400C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAuresNot Available143T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSplitNot Available1442C->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKambosNot Available148C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePalestrinaNot Available170G>AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMetapontoNot Available172G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMusashinoNot Available185C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahiNot Available202G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (202), Ferrara INot Available202G->A / 376A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMurcia OristanoNot Available209A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUbe KonanNot Available241C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagosantoNot Available242G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGuangzhouNot Available274C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHammersmithNot Available323T->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSinnaiNot Available34G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (680)Not Available376A->G / 680G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (968), Betica,Selma, GuantanamoNot Available376A->G / 968T->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSalerno PyrgosNot Available383T>GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseQuing YanNot Available392G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagesNot Available40G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIleshaNot Available466G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMahidolNot Available487G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMalagaNot Available542A->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSibariNot Available634A->GADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMexico CityNot Available680G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNanningNot Available703C->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeattle, Lodi, Modena, Ferrara II, Athens-likeNot Available844G->CADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBajo MaumereNot Available844G->TADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontalbanoNot Available854G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKalyan-Kerala, Jamnaga, RohiniNot Available949G->AADR InferredIncreased risk of hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGaoheNot Available95A->GADR InferredIncreased risk of hemolytic anemia.Details
Cytochrome P450 2C9CYP2C9*6Not Available818delAEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*15Not Available485C>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*25Not Available353_362delAGAAATGGAAEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*35Not Available374G>T / 430C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*2Not Available430C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*4Not Available1076T>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*5Not Available1080C>GEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*8Not Available449G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*11Not Available1003C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*12Not Available1465C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*13Not Available269T>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*14Not Available374G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*16Not Available895A>GEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*18Not Available1075A>C / 1190A>C  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*26Not Available389C>GEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*28Not Available641A>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*30Not Available1429G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*33Not Available395G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinGlipizide may increase the anticoagulant activities of (R)-warfarin.Experimental
(S)-WarfarinGlipizide may increase the anticoagulant activities of (S)-Warfarin.Experimental, Investigational
2,4-thiazolidinedione2,4-thiazolidinedione may increase the hypoglycemic activities of Glipizide.Investigational
4-hydroxycoumarinGlipizide may increase the anticoagulant activities of 4-hydroxycoumarin.Experimental
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe therapeutic efficacy of Glipizide can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.Experimental
AbirateroneThe metabolism of Glipizide can be decreased when combined with Abiraterone.Approved
AcarboseAcarbose may increase the hypoglycemic activities of Glipizide.Approved, Investigational
AcebutololAcebutolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
AceclofenacThe protein binding of Glipizide can be decreased when combined with Aceclofenac.Approved, Investigational
AcemetacinThe protein binding of Glipizide can be decreased when combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolGlipizide may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Glipizide.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe therapeutic efficacy of Glipizide can be increased when used in combination with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Glipizide.Approved, Vet Approved
AICA ribonucleotideAICA ribonucleotide may increase the hypoglycemic activities of Glipizide.Experimental, Investigational
AlaproclateAlaproclate may increase the hypoglycemic activities of Glipizide.Experimental
AlbiglutideAlbiglutide may increase the hypoglycemic activities of Glipizide.Approved
AlclofenacThe protein binding of Glipizide can be decreased when combined with Alclofenac.Approved, Withdrawn
AlminoprofenThe protein binding of Glipizide can be decreased when combined with Alminoprofen.Experimental
AlogliptinAlogliptin may increase the hypoglycemic activities of Glipizide.Approved
AloxiprinAloxiprin may increase the hypoglycemic activities of Glipizide.Experimental
AlprenololAlprenolol may increase the hypoglycemic activities of Glipizide.Approved, Withdrawn
Aluminium clofibrateThe risk or severity of hypoglycemia can be increased when Aluminium clofibrate is combined with Glipizide.Experimental
AMG-222AMG-222 may increase the hypoglycemic activities of Glipizide.Investigational
AmineptineAmineptine may decrease the hypoglycemic activities of Glipizide.Illicit, Withdrawn
AminophenazoneThe protein binding of Glipizide can be decreased when combined with Aminophenazone.Approved, Withdrawn
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Glipizide.Approved
AmiodaroneThe metabolism of Glipizide can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may decrease the hypoglycemic activities of Glipizide.Approved
AmitriptylinoxideAmitriptylinoxide may decrease the hypoglycemic activities of Glipizide.Approved, Investigational
AmoxapineAmoxapine may decrease the hypoglycemic activities of Glipizide.Approved
AmprenavirThe metabolism of Glipizide can be decreased when combined with Amprenavir.Approved, Investigational
AnagliptinAnagliptin may increase the hypoglycemic activities of Glipizide.Investigational
AnisodamineAnisodamine may increase the hypoglycemic activities of Glipizide.Investigational
AntipyrineThe protein binding of Glipizide can be decreased when combined with Antipyrine.Approved, Investigational
AntrafenineThe protein binding of Glipizide can be decreased when combined with Antrafenine.Approved
ApalutamideThe serum concentration of Glipizide can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Glipizide can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Glipizide can be decreased when used in combination with Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the hypoglycemic activities of Glipizide.Investigational
Arsenic trioxideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Asenapine.Approved
AtazanavirThe metabolism of Glipizide can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypoglycemic activities of Glipizide.Approved
AzapropazoneThe protein binding of Glipizide can be decreased when combined with Azapropazone.Withdrawn
AzosemideThe therapeutic efficacy of Glipizide can be increased when used in combination with Azosemide.Investigational
BalaglitazoneThe therapeutic efficacy of Glipizide can be increased when used in combination with Balaglitazone.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
BefunololBefunolol may increase the hypoglycemic activities of Glipizide.Experimental
Bempedoic acidBempedoic acid may increase the hypoglycemic activities of Glipizide.Investigational
BendazacThe protein binding of Glipizide can be decreased when combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Bendroflumethiazide.Approved
BenfluorexBenfluorex may increase the hypoglycemic activities of Glipizide.Investigational, Withdrawn
BenmoxinBenmoxin may increase the hypoglycemic activities of Glipizide.Withdrawn
BenorilateThe protein binding of Glipizide can be decreased when combined with Benorilate.Experimental
BenoxaprofenThe protein binding of Glipizide can be decreased when combined with Benoxaprofen.Withdrawn
BenzthiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Benzthiazide.Approved
BenzydamineThe protein binding of Glipizide can be decreased when combined with Benzydamine.Approved
BesifloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Besifloxacin.Approved
BetamethasoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
BevantololBevantolol may increase the hypoglycemic activities of Glipizide.Approved
BezafibrateThe risk or severity of hypoglycemia can be increased when Bezafibrate is combined with Glipizide.Approved, Investigational
BicalutamideThe metabolism of Glipizide can be decreased when combined with Bicalutamide.Approved
BisoprololBisoprolol may increase the hypoglycemic activities of Glipizide.Approved
BoceprevirThe metabolism of Glipizide can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the hypoglycemic activities of Glipizide.Approved
BosentanThe serum concentration of Glipizide can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe therapeutic efficacy of Glipizide can be decreased when used in combination with Brexpiprazole.Approved, Investigational
BromfenacThe protein binding of Glipizide can be decreased when combined with Bromfenac.Approved
BromocriptineBromocriptine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
BucindololBucindolol may increase the hypoglycemic activities of Glipizide.Investigational
BufexamacThe protein binding of Glipizide can be decreased when combined with Bufexamac.Approved, Experimental
BuforminBuformin may increase the hypoglycemic activities of Glipizide.Investigational, Withdrawn
BufuralolBufuralol may increase the hypoglycemic activities of Glipizide.Experimental, Investigational
BumadizoneThe protein binding of Glipizide can be decreased when combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Glipizide can be increased when used in combination with Bumetanide.Approved
BupranololBupranolol may increase the hypoglycemic activities of Glipizide.Approved
BuserelinThe therapeutic efficacy of Glipizide can be decreased when used in combination with Buserelin.Approved, Investigational
ButriptylineButriptyline may decrease the hypoglycemic activities of Glipizide.Approved
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Glipizide.Approved
CapecitabineThe metabolism of Glipizide can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe serum concentration of Glipizide can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the hypoglycemic activities of Glipizide.Experimental, Investigational
CarbocisteineThe risk or severity of adverse effects can be increased when Glipizide is combined with Carbocisteine.Approved, Investigational
CarbutamideCarbutamide may increase the hypoglycemic activities of Glipizide.Experimental
CarmegliptinCarmegliptin may increase the hypoglycemic activities of Glipizide.Investigational
CaroxazoneCaroxazone may increase the hypoglycemic activities of Glipizide.Withdrawn
CarprofenThe protein binding of Glipizide can be decreased when combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypoglycemic activities of Glipizide.Approved
CarvedilolCarvedilol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
CelecoxibThe protein binding of Glipizide can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
CeritinibThe serum concentration of Glipizide can be increased when it is combined with Ceritinib.Approved
Chloramine-TThe therapeutic efficacy of Glipizide can be increased when used in combination with Chloramine-T.Vet Approved
ChloramphenicolThe metabolism of Glipizide can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpropamideChlorpropamide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
ChlorsulfaquinoxalineThe therapeutic efficacy of Glipizide can be increased when used in combination with Chlorsulfaquinoxaline.Investigational
ChlorthalidoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Chlorthalidone.Approved
Choline magnesium trisalicylateThe protein binding of Glipizide can be decreased when combined with Choline magnesium trisalicylate.Approved
CiglitazoneThe therapeutic efficacy of Glipizide can be increased when used in combination with Ciglitazone.Experimental
CimetidineThe serum concentration of Glipizide can be increased when it is combined with Cimetidine.Approved, Investigational
CimicoxibThe protein binding of Glipizide can be decreased when combined with Cimicoxib.Investigational
CinoxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Cinoxacin.Approved, Investigational, Withdrawn
CiprofibrateThe risk or severity of hypoglycemia can be increased when Ciprofibrate is combined with Glipizide.Approved, Investigational
CiprofloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Ciprofloxacin.Approved, Investigational
CitalopramCitalopram may increase the hypoglycemic activities of Glipizide.Approved
ClarithromycinThe serum concentration of Glipizide can be increased when it is combined with Clarithromycin.Approved
ClofenamideThe therapeutic efficacy of Glipizide can be increased when used in combination with Clofenamide.Experimental
ClofibrateThe risk or severity of hypoglycemia can be increased when Clofibrate is combined with Glipizide.Approved, Investigational
ClofibrideThe risk or severity of hypoglycemia can be increased when Clofibride is combined with Glipizide.Experimental
ClomipramineClomipramine may decrease the hypoglycemic activities of Glipizide.Approved, Investigational, Vet Approved
ClonixinThe protein binding of Glipizide can be decreased when combined with Clonixin.Approved
ClopamideThe therapeutic efficacy of Glipizide can be increased when used in combination with Clopamide.Experimental
CloranololCloranolol may increase the hypoglycemic activities of Glipizide.Experimental
ClorexoloneThe therapeutic efficacy of Glipizide can be increased when used in combination with Clorexolone.Experimental
ClorindioneGlipizide may increase the anticoagulant activities of Clorindione.Experimental
ClorsulonThe therapeutic efficacy of Glipizide can be increased when used in combination with Clorsulon.Vet Approved
ClotrimazoleThe metabolism of Glipizide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Clozapine.Approved
CobicistatThe metabolism of Glipizide can be decreased when combined with Cobicistat.Approved
ColesevelamThe serum concentration of Glipizide can be decreased when it is combined with Colesevelam.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Glipizide.Approved, Investigational
CorticotropinThe therapeutic efficacy of Glipizide can be decreased when used in combination with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Glipizide can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Glipizide can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Glipizide can be decreased when combined with Curcumin.Approved, Investigational
CyclobenzaprineCyclobenzaprine may decrease the hypoglycemic activities of Glipizide.Approved
CyclopenthiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Glipizide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe therapeutic efficacy of Glipizide can be increased when used in combination with Cyclothiazide.Approved
Cyproterone acetateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Glipizide can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe therapeutic efficacy of Glipizide can be decreased when used in combination with Danazol.Approved
DapagliflozinDapagliflozin may increase the hypoglycemic activities of Glipizide.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Glipizide.Investigational
DarunavirThe metabolism of Glipizide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Glipizide can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Glipizide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Glipizide can be decreased when combined with Delavirdine.Approved
DersalazineDersalazine may increase the hypoglycemic activities of Glipizide.Investigational
DesipramineDesipramine may decrease the hypoglycemic activities of Glipizide.Approved, Investigational
DesogestrelThe therapeutic efficacy of Glipizide can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
DexamethasoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DexibuprofenThe protein binding of Glipizide can be decreased when combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe protein binding of Glipizide can be decreased when combined with Dexketoprofen.Approved, Investigational
DiazoxideThe therapeutic efficacy of Glipizide can be increased when used in combination with Diazoxide.Approved
DibenzepinDibenzepin may decrease the hypoglycemic activities of Glipizide.Experimental
DiclofenacThe protein binding of Glipizide can be decreased when combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe therapeutic efficacy of Glipizide can be increased when used in combination with Diclofenamide.Approved, Investigational
DicoumarolGlipizide may increase the anticoagulant activities of Dicoumarol.Approved
DienogestThe therapeutic efficacy of Glipizide can be decreased when used in combination with Dienogest.Approved
DifenpiramideThe protein binding of Glipizide can be decreased when combined with Difenpiramide.Experimental
DifloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Difloxacin.Vet Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Glipizide.Approved, Investigational
DiltiazemThe metabolism of Glipizide can be decreased when combined with Diltiazem.Approved, Investigational
DimetacrineDimetacrine may decrease the hypoglycemic activities of Glipizide.Approved, Withdrawn
DiphenadioneGlipizide may increase the anticoagulant activities of Diphenadione.Experimental
DisopyramideDisopyramide may increase the hypoglycemic activities of Glipizide.Approved
DosulepinDosulepin may decrease the hypoglycemic activities of Glipizide.Approved
DoxepinDoxepin may decrease the hypoglycemic activities of Glipizide.Approved, Investigational
DoxycyclineThe metabolism of Glipizide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Glipizide can be decreased when combined with Dronedarone.Approved
DrospirenoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Drospirenone.Approved
DroxicamThe protein binding of Glipizide can be decreased when combined with Droxicam.Withdrawn
DulaglutideDulaglutide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
DuloxetineDuloxetine may increase the hypoglycemic activities of Glipizide.Approved
DutogliptinDutogliptin may increase the hypoglycemic activities of Glipizide.Investigational
EfavirenzThe serum concentration of Glipizide can be decreased when it is combined with Efavirenz.Approved, Investigational
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Glipizide.Approved
EnglitazoneEnglitazone may increase the hypoglycemic activities of Glipizide.Experimental
EnoxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Glipizide can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the hypoglycemic activities of Glipizide.Experimental
EpinephrineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EpirizoleThe protein binding of Glipizide can be decreased when combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Epitizide.Experimental
ErtugliflozinErtugliflozin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
ErythromycinThe metabolism of Glipizide can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololEsatenolol may increase the hypoglycemic activities of Glipizide.Experimental
EscitalopramEscitalopram may increase the hypoglycemic activities of Glipizide.Approved, Investigational
EsmololEsmolol may increase the hypoglycemic activities of Glipizide.Approved
EstradiolThe therapeutic efficacy of Glipizide can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
Estrone sulfateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Glipizide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
EthanolThe risk or severity of adverse effects can be increased when Glipizide is combined with Ethanol.Approved
EthenzamideThe protein binding of Glipizide can be decreased when combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Glipizide can be decreased when it is combined with Ethinyl Estradiol.Approved
EthoxzolamideThe therapeutic efficacy of Glipizide can be increased when used in combination with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateGlipizide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Ethynodiol diacetate.Approved
EtodolacThe protein binding of Glipizide can be decreased when combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe protein binding of Glipizide can be decreased when combined with Etofenamate.Approved, Investigational
EtofibrateThe risk or severity of hypoglycemia can be increased when Etofibrate is combined with Glipizide.Approved
EtonogestrelThe therapeutic efficacy of Glipizide can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibThe protein binding of Glipizide can be decreased when combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Glipizide can be decreased when it is combined with Etravirine.Approved
EverolimusThe therapeutic efficacy of Glipizide can be decreased when used in combination with Everolimus.Approved
EvogliptinEvogliptin may increase the hypoglycemic activities of Glipizide.Investigational
ExenatideExenatide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
FelbamateThe metabolism of Glipizide can be decreased when combined with Felbamate.Approved
FelbinacThe protein binding of Glipizide can be decreased when combined with Felbinac.Experimental
FenbufenThe protein binding of Glipizide can be decreased when combined with Fenbufen.Approved
FenofibrateThe risk or severity of hypoglycemia can be increased when Fenofibrate is combined with Glipizide.Approved
Fenofibric acidThe risk or severity of hypoglycemia can be increased when Fenofibric acid is combined with Glipizide.Approved
FenoprofenThe protein binding of Glipizide can be decreased when combined with Fenoprofen.Approved
FenquizoneThe therapeutic efficacy of Glipizide can be increased when used in combination with Fenquizone.Experimental
FentiazacThe protein binding of Glipizide can be decreased when combined with Fentiazac.Experimental
FeprazoneThe protein binding of Glipizide can be decreased when combined with Feprazone.Experimental
FirocoxibThe protein binding of Glipizide can be decreased when combined with Firocoxib.Experimental, Vet Approved
FleroxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Fleroxacin.Approved
FloctafenineThe protein binding of Glipizide can be decreased when combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Glipizide can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Glipizide can be increased when it is combined with Fluconazole.Approved, Investigational
FludrocortisoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
FluindioneGlipizide may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineThe therapeutic efficacy of Glipizide can be increased when used in combination with Flumequine.Withdrawn
FlunixinThe protein binding of Glipizide can be decreased when combined with Flunixin.Vet Approved
FlunoxaprofenThe protein binding of Glipizide can be decreased when combined with Flunoxaprofen.Experimental
FluorouracilThe metabolism of Glipizide can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the hypoglycemic activities of Glipizide.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Glipizide.Approved, Illicit
FlurbiprofenThe protein binding of Glipizide can be decreased when combined with Flurbiprofen.Approved, Investigational
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Glipizide can be decreased when used in combination with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Glipizide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Glipizide can be increased when combined with Fosphenytoin.Approved, Investigational
FurazolidoneFurazolidone may increase the hypoglycemic activities of Glipizide.Approved, Investigational, Vet Approved
FurosemideThe therapeutic efficacy of Glipizide can be increased when used in combination with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Glipizide can be increased when it is combined with Fusidic Acid.Approved, Investigational
GarenoxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Garenoxacin.Investigational
GatifloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Gatifloxacin.Approved, Investigational
GemfibrozilThe risk or severity of hypoglycemia can be increased when Gemfibrozil is combined with Glipizide.Approved
GemifloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Gemifloxacin.Approved, Investigational
GemigliptinGemigliptin may increase the hypoglycemic activities of Glipizide.Investigational
GlibornurideGlibornuride may increase the hypoglycemic activities of Glipizide.Investigational, Withdrawn
GliclazideGlipizide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGlimepiride may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneGliquidone may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlisoxepideGlisoxepide may increase the hypoglycemic activities of Glipizide.Investigational
GLPG-0492GLPG-0492 may increase the hypoglycemic activities of Glipizide.Investigational
GlyburideGlyburide may increase the hypoglycemic activities of Glipizide.Approved
GlycodiazineThe therapeutic efficacy of Glipizide can be increased when used in combination with Glycodiazine.Approved, Investigational
GoserelinThe therapeutic efficacy of Glipizide can be decreased when used in combination with Goserelin.Approved
GosogliptinGosogliptin may increase the hypoglycemic activities of Glipizide.Investigational
GrepafloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalGuacetisal may increase the hypoglycemic activities of Glipizide.Experimental
Guar gumGuar gum may increase the hypoglycemic activities of Glipizide.Experimental
HarmalineHarmaline may increase the hypoglycemic activities of Glipizide.Experimental
HistrelinThe therapeutic efficacy of Glipizide can be decreased when used in combination with Histrelin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Glipizide.Experimental
HydrochlorothiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Hydroflumethiazide.Approved, Investigational
HydroxyfasudilThe therapeutic efficacy of Glipizide can be increased when used in combination with Hydroxyfasudil.Experimental
Hydroxyprogesterone caproateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
IbuprofenThe protein binding of Glipizide can be decreased when combined with Ibuprofen.Approved
IbuproxamThe protein binding of Glipizide can be decreased when combined with Ibuproxam.Withdrawn
IcosapentThe protein binding of Glipizide can be decreased when combined with Icosapent.Approved, Nutraceutical
IdelalisibThe metabolism of Glipizide can be decreased when combined with Idelalisib.Approved
IloperidoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Iloperidone.Approved
ImatinibThe metabolism of Glipizide can be decreased when combined with Imatinib.Approved
Imidazole salicylateThe protein binding of Glipizide can be decreased when combined with Imidazole salicylate.Experimental
ImipramineImipramine may decrease the hypoglycemic activities of Glipizide.Approved
Imipramine oxideImipramine oxide may decrease the hypoglycemic activities of Glipizide.Experimental
IndalpineIndalpine may increase the hypoglycemic activities of Glipizide.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Indapamide.Approved
IndenololIndenolol may increase the hypoglycemic activities of Glipizide.Withdrawn
IndinavirThe metabolism of Glipizide can be decreased when combined with Indinavir.Approved
IndobufenThe protein binding of Glipizide can be decreased when combined with Indobufen.Investigational
IndomethacinThe protein binding of Glipizide can be decreased when combined with Indomethacin.Approved, Investigational
IndoprofenThe protein binding of Glipizide can be decreased when combined with Indoprofen.Withdrawn
Insulin AspartGlipizide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin BeefInsulin Beef may increase the hypoglycemic activities of Glipizide.Approved
Insulin DegludecInsulin Degludec may increase the hypoglycemic activities of Glipizide.Approved
Insulin DetemirGlipizide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Glipizide.Approved
Insulin GlulisineGlipizide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanInsulin Human may increase the hypoglycemic activities of Glipizide.Approved, Investigational
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Glipizide.Approved
Insulin peglisproInsulin peglispro may increase the hypoglycemic activities of Glipizide.Investigational
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Glipizide.Approved
IprindoleIprindole may decrease the hypoglycemic activities of Glipizide.Experimental
IproniazidIproniazid may increase the hypoglycemic activities of Glipizide.Withdrawn
IsavuconazoleThe serum concentration of Glipizide can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Glipizide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Glipizide.Approved
IsoniazidThe metabolism of Glipizide can be decreased when combined with Isoniazid.Approved, Investigational
IsoxicamThe protein binding of Glipizide can be decreased when combined with Isoxicam.Withdrawn
ItraconazoleThe metabolism of Glipizide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Glipizide can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe protein binding of Glipizide can be decreased when combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Glipizide can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe protein binding of Glipizide can be decreased when combined with Ketoprofen.Approved, Vet Approved
KetorolacThe protein binding of Glipizide can be decreased when combined with Ketorolac.Approved
KRP-104KRP-104 may increase the hypoglycemic activities of Glipizide.Investigational
LabetalolLabetalol may increase the hypoglycemic activities of Glipizide.Approved
LamotrigineThe serum concentration of Glipizide can be decreased when it is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the hypoglycemic activities of Glipizide.Investigational
LanreotideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Lanreotide.Approved
LeuprolideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Leuprolide.Approved, Investigational
LevobetaxololLevobetaxolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
LevobunololLevobunolol may increase the hypoglycemic activities of Glipizide.Approved
LevofloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Glipizide.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Glipizide can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LinagliptinLinagliptin may increase the hypoglycemic activities of Glipizide.Approved
LinezolidLinezolid may increase the hypoglycemic activities of Glipizide.Approved, Investigational
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Glipizide.Approved, Investigational, Nutraceutical
LiraglutideLiraglutide may increase the hypoglycemic activities of Glipizide.Approved
LixisenatideLixisenatide may increase the hypoglycemic activities of Glipizide.Approved
LobeglitazoneThe therapeutic efficacy of Glipizide can be increased when used in combination with Lobeglitazone.Approved, Investigational
LofepramineLofepramine may decrease the hypoglycemic activities of Glipizide.Experimental
LomefloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Lomefloxacin.Approved, Investigational
LonazolacThe protein binding of Glipizide can be decreased when combined with Lonazolac.Experimental
LopinavirThe metabolism of Glipizide can be decreased when combined with Lopinavir.Approved
LornoxicamThe protein binding of Glipizide can be decreased when combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Glipizide can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Glipizide can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe protein binding of Glipizide can be decreased when combined with Loxoprofen.Approved, Investigational
LuliconazoleThe serum concentration of Glipizide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Glipizide can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe protein binding of Glipizide can be decreased when combined with Lumiracoxib.Approved, Investigational
LurasidoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Lurasidone.Approved, Investigational
MafenideThe therapeutic efficacy of Glipizide can be increased when used in combination with Mafenide.Approved, Vet Approved
Magnesium salicylateThe protein binding of Glipizide can be decreased when combined with Magnesium salicylate.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Glipizide.Withdrawn
MebutizideThe therapeutic efficacy of Glipizide can be increased when used in combination with Mebutizide.Experimental
MecaserminGlipizide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidThe protein binding of Glipizide can be decreased when combined with Meclofenamic acid.Approved, Vet Approved
MedrogestoneThe serum concentration of Glipizide can be decreased when it is combined with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidThe protein binding of Glipizide can be decreased when combined with Mefenamic acid.Approved
MefrusideThe therapeutic efficacy of Glipizide can be increased when used in combination with Mefruside.Experimental
Megestrol acetateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelitracenMelitracen may decrease the hypoglycemic activities of Glipizide.Experimental, Investigational
MeloxicamThe protein binding of Glipizide can be decreased when combined with Meloxicam.Approved, Vet Approved
MepindololMepindolol may increase the hypoglycemic activities of Glipizide.Experimental
MesalazineMesalazine may increase the hypoglycemic activities of Glipizide.Approved
MesteroloneMesterolone may increase the hypoglycemic activities of Glipizide.Experimental
MestranolThe therapeutic efficacy of Glipizide can be decreased when used in combination with Mestranol.Approved
MetahexamideMetahexamide may increase the hypoglycemic activities of Glipizide.Experimental
MetamizoleThe protein binding of Glipizide can be decreased when combined with Metamizole.Approved, Investigational, Withdrawn
MetforminMetformin may increase the hypoglycemic activities of Glipizide.Approved
MethotrimeprazineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
MethyclothiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Methyclothiazide.Approved
Methyl salicylateMethyl salicylate may increase the hypoglycemic activities of Glipizide.Approved, Vet Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Glipizide.Approved, Investigational
MethylprednisoloneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Glipizide.Approved
MeticraneThe therapeutic efficacy of Glipizide can be increased when used in combination with Meticrane.Experimental
MetipranololMetipranolol may increase the hypoglycemic activities of Glipizide.Approved
MetolazoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Metolazone.Approved
MetoprololMetoprolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
MetreleptinMetreleptin may increase the hypoglycemic activities of Glipizide.Approved
MibefradilThe metabolism of Glipizide can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleMiconazole may increase the hypoglycemic activities of Glipizide.Approved, Investigational, Vet Approved
MidostaurinThe metabolism of Glipizide can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Glipizide can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolMiglitol may increase the hypoglycemic activities of Glipizide.Approved
MilnacipranMilnacipran may increase the hypoglycemic activities of Glipizide.Approved, Investigational
MinaprineMinaprine may increase the hypoglycemic activities of Glipizide.Approved
MitiglinideMitiglinide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
MitotaneThe serum concentration of Glipizide can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
ModafinilThe serum concentration of Glipizide can be decreased when it is combined with Modafinil.Approved, Investigational
MofebutazoneThe protein binding of Glipizide can be decreased when combined with Mofebutazone.Experimental
MorniflumateThe protein binding of Glipizide can be decreased when combined with Morniflumate.Approved
MoxifloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Moxifloxacin.Approved, Investigational
NabiloneThe metabolism of Glipizide can be decreased when combined with Nabilone.Approved, Investigational
NabumetoneThe protein binding of Glipizide can be decreased when combined with Nabumetone.Approved
NadololNadolol may increase the hypoglycemic activities of Glipizide.Approved
NafcillinThe serum concentration of Glipizide can be decreased when it is combined with Nafcillin.Approved, Investigational
Nalidixic AcidThe therapeutic efficacy of Glipizide can be increased when used in combination with Nalidixic Acid.Approved, Investigational
NaloxoneThe metabolism of Glipizide can be decreased when combined with Naloxone.Approved, Vet Approved
NandroloneNandrolone may increase the hypoglycemic activities of Glipizide.Experimental, Investigational
Nandrolone decanoateNandrolone decanoate may increase the hypoglycemic activities of Glipizide.Approved, Illicit
NaproxenThe protein binding of Glipizide can be decreased when combined with Naproxen.Approved, Vet Approved
NateglinideNateglinide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
NBI-6024NBI-6024 may increase the hypoglycemic activities of Glipizide.Investigational
NebivololNebivolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
NefazodoneThe metabolism of Glipizide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Glipizide can be decreased when it is combined with Nelfinavir.Approved
NemonoxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Nemonoxacin.Investigational
NepafenacThe protein binding of Glipizide can be decreased when combined with Nepafenac.Approved, Investigational
NetoglitazoneThe therapeutic efficacy of Glipizide can be increased when used in combination with Netoglitazone.Experimental
NetupitantThe serum concentration of Glipizide can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Glipizide can be increased when combined with Nevirapine.Approved
NiacinThe therapeutic efficacy of Glipizide can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypoglycemic activities of Glipizide.Withdrawn
NicardipineThe metabolism of Glipizide can be decreased when combined with Nicardipine.Approved, Investigational
NifenazoneThe protein binding of Glipizide can be decreased when combined with Nifenazone.Experimental
Niflumic AcidThe protein binding of Glipizide can be decreased when combined with Niflumic Acid.Approved
NilotinibThe metabolism of Glipizide can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe protein binding of Glipizide can be decreased when combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Glipizide.Investigational
NN344NN344 may increase the hypoglycemic activities of Glipizide.Investigational
NorethisteroneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Norethisterone.Approved
NorfloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Norfloxacin.Approved
NorgestimateThe therapeutic efficacy of Glipizide can be decreased when used in combination with Norgestimate.Approved, Investigational
NortriptylineNortriptyline may decrease the hypoglycemic activities of Glipizide.Approved
NS-398The protein binding of Glipizide can be decreased when combined with NS-398.Experimental
OctamoxinOctamoxin may increase the hypoglycemic activities of Glipizide.Withdrawn
OctreotideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Octreotide.Approved, Investigational
OfloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Ofloxacin.Approved
OlanzapineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Glipizide can be decreased when combined with Olaparib.Approved
OlsalazineOlsalazine may increase the hypoglycemic activities of Glipizide.Approved
OmarigliptinOmarigliptin may increase the hypoglycemic activities of Glipizide.Investigational
OpipramolOpipramol may decrease the hypoglycemic activities of Glipizide.Investigational
OrbifloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Orbifloxacin.Vet Approved
OsimertinibThe serum concentration of Glipizide can be increased when it is combined with Osimertinib.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Glipizide.Approved, Investigational
OxaprotilineOxaprotiline may decrease the hypoglycemic activities of Glipizide.Experimental
OxaprozinThe protein binding of Glipizide can be decreased when combined with Oxaprozin.Approved
OxcarbazepineThe serum concentration of Glipizide can be decreased when it is combined with Oxcarbazepine.Approved
Oxolinic acidThe therapeutic efficacy of Glipizide can be increased when used in combination with Oxolinic acid.Experimental
OxprenololOxprenolol may increase the hypoglycemic activities of Glipizide.Approved
OxymetholoneOxymetholone may increase the hypoglycemic activities of Glipizide.Approved, Illicit
OxyphenbutazoneThe protein binding of Glipizide can be decreased when combined with Oxyphenbutazone.Approved, Withdrawn
PalbociclibThe serum concentration of Glipizide can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Paliperidone.Approved
ParecoxibThe protein binding of Glipizide can be decreased when combined with Parecoxib.Approved
PargylinePargyline may increase the hypoglycemic activities of Glipizide.Approved
ParoxetineParoxetine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
PasireotideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Pasireotide.Approved
PazufloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Pazufloxacin.Investigational
PefloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Pefloxacin.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Glipizide.Approved
PenbutololPenbutolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
PentamidineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Pentamidine.Approved, Investigational
PentobarbitalThe metabolism of Glipizide can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Glipizide.Approved
PhenforminPhenformin may increase the hypoglycemic activities of Glipizide.Approved, Investigational, Withdrawn
PhenindioneGlipizide may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the hypoglycemic activities of Glipizide.Withdrawn
PhenobarbitalThe serum concentration of Glipizide can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Glipizide.Withdrawn
PhenprocoumonGlipizide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylatePhenyl aminosalicylate may increase the hypoglycemic activities of Glipizide.Approved
PhenylbutazoneThe protein binding of Glipizide can be decreased when combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Glipizide can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhthalylsulfathiazoleThe therapeutic efficacy of Glipizide can be increased when used in combination with Phthalylsulfathiazole.Experimental
PindololPindolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Glipizide can be increased when used in combination with Pioglitazone.Approved, Investigational
Pipemidic acidThe therapeutic efficacy of Glipizide can be increased when used in combination with Pipemidic acid.Experimental
PiperazineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Piperazine.Approved, Vet Approved
PiperineThe metabolism of Glipizide can be decreased when combined with Piperine.Investigational
PipotiazineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Pipotiazine.Approved, Investigational
PiretanideThe therapeutic efficacy of Glipizide can be increased when used in combination with Piretanide.Approved
PirlindolePirlindole may increase the hypoglycemic activities of Glipizide.Approved
Piromidic acidThe therapeutic efficacy of Glipizide can be increased when used in combination with Piromidic acid.Experimental
PiroxicamThe protein binding of Glipizide can be decreased when combined with Piroxicam.Approved, Investigational
PirprofenThe protein binding of Glipizide can be decreased when combined with Pirprofen.Experimental
PitolisantThe serum concentration of Glipizide can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Glipizide.Withdrawn
PolythiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Polythiazide.Approved
PosaconazolePosaconazole may increase the hypoglycemic activities of Glipizide.Approved, Investigational, Vet Approved
PractololPractolol may increase the hypoglycemic activities of Glipizide.Approved
PramlintidePramlintide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
PranoprofenThe protein binding of Glipizide can be decreased when combined with Pranoprofen.Experimental, Investigational
PrednisoloneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of heart failure can be increased when Pregabalin is combined with Glipizide.Approved, Illicit, Investigational
PrimidoneThe serum concentration of Glipizide can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe protein binding of Glipizide can be decreased when combined with Probenecid.Approved, Investigational
ProgesteroneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinThe protein binding of Glipizide can be decreased when combined with Proglumetacin.Experimental
PropacetamolThe protein binding of Glipizide can be decreased when combined with Propacetamol.Approved, Investigational
PropafenonePropafenone may increase the hypoglycemic activities of Glipizide.Approved
PropranololPropranolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
PropyphenazoneThe protein binding of Glipizide can be decreased when combined with Propyphenazone.Experimental
ProquazoneThe protein binding of Glipizide can be decreased when combined with Proquazone.Experimental
ProtriptylineProtriptyline may decrease the hypoglycemic activities of Glipizide.Approved
PrulifloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Prulifloxacin.Investigational
QuetiapineThe therapeutic efficacy of Glipizide can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Quinethazone.Approved
QuinineThe metabolism of Glipizide can be increased when combined with Quinine.Approved
QuinupramineQuinupramine may decrease the hypoglycemic activities of Glipizide.Experimental
RanitidineThe serum concentration of Glipizide can be increased when it is combined with Ranitidine.Approved
RasagilineRasagiline may increase the hypoglycemic activities of Glipizide.Approved
RepaglinideRepaglinide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
RifamycinThe metabolism of Glipizide can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Glipizide can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Glipizide can be increased when combined with Rifaximin.Approved, Investigational
RimexoloneThe metabolism of Glipizide can be increased when combined with Rimexolone.Approved
RisperidoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Risperidone.Approved, Investigational
RitanserinRitanserin may increase the hypoglycemic activities of Glipizide.Investigational
RitonavirThe serum concentration of Glipizide can be decreased when it is combined with Ritonavir.Approved, Investigational
RivoglitazoneThe therapeutic efficacy of Glipizide can be increased when used in combination with Rivoglitazone.Experimental, Investigational
RobenacoxibThe protein binding of Glipizide can be decreased when combined with Robenacoxib.Experimental, Vet Approved
RofecoxibThe protein binding of Glipizide can be decreased when combined with Rofecoxib.Approved, Investigational, Withdrawn
RonifibrateThe risk or severity of hypoglycemia can be increased when Ronifibrate is combined with Glipizide.Experimental
RosiglitazoneThe therapeutic efficacy of Glipizide can be increased when used in combination with Rosiglitazone.Approved, Investigational
RosoxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Rosoxacin.Approved, Investigational
RosuvastatinThe therapeutic efficacy of Glipizide can be increased when used in combination with Rosuvastatin.Approved
RufloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Rufloxacin.Experimental
SafinamideSafinamide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
SafrazineSafrazine may increase the hypoglycemic activities of Glipizide.Withdrawn
SalicylamideThe protein binding of Glipizide can be decreased when combined with Salicylamide.Approved
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Glipizide.Approved, Investigational, Vet Approved
SalsalateThe protein binding of Glipizide can be decreased when combined with Salsalate.Approved
SaquinavirThe metabolism of Glipizide can be decreased when combined with Saquinavir.Approved, Investigational
SarafloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Sarafloxacin.Vet Approved, Withdrawn
SarilumabThe therapeutic efficacy of Glipizide can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Glipizide.Approved
SC-236The protein binding of Glipizide can be decreased when combined with SC-236.Experimental, Investigational
SecobarbitalThe metabolism of Glipizide can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypoglycemic activities of Glipizide.Approved, Investigational, Vet Approved
SemaglutideSemaglutide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
SertralineSertraline may increase the hypoglycemic activities of Glipizide.Approved
SetrobuvirThe therapeutic efficacy of Glipizide can be increased when used in combination with Setrobuvir.Investigational
SildenafilThe therapeutic efficacy of Glipizide can be increased when used in combination with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Glipizide can be decreased when it is combined with Siltuximab.Approved, Investigational
Silver sulfadiazineThe therapeutic efficacy of Glipizide can be increased when used in combination with Silver sulfadiazine.Approved, Vet Approved
SimeprevirThe serum concentration of Glipizide can be increased when it is combined with Simeprevir.Approved
SimfibrateThe risk or severity of hypoglycemia can be increased when Simfibrate is combined with Glipizide.Experimental
SirolimusThe therapeutic efficacy of Glipizide can be decreased when used in combination with Sirolimus.Approved, Investigational
SitafloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Sitafloxacin.Experimental, Investigational
SitagliptinSitagliptin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
SotagliflozinSotagliflozin may increase the hypoglycemic activities of Glipizide.Investigational
SotalolSotalol may increase the hypoglycemic activities of Glipizide.Approved
SparfloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Sparfloxacin.Approved, Investigational
St. John's WortThe serum concentration of Glipizide can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneStanolone may increase the hypoglycemic activities of Glipizide.Illicit, Investigational
StanozololStanozolol may increase the hypoglycemic activities of Glipizide.Approved, Vet Approved
StiripentolThe serum concentration of Glipizide can be increased when it is combined with Stiripentol.Approved
SuccinylsulfathiazoleThe therapeutic efficacy of Glipizide can be increased when used in combination with Succinylsulfathiazole.Experimental
SulfacetamideThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfacetamide.Approved
SulfachlorpyridazineThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfachlorpyridazine.Vet Approved
SulfacytineThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfacytine.Approved
SulfadiazineThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfadiazine.Approved, Investigational, Vet Approved
SulfadicramideThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfadicramide.Experimental
SulfadimethoxineThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfadimethoxine.Approved, Vet Approved
SulfadoxineThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfadoxine.Approved, Investigational
SulfaethoxypyridazineThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfaethoxypyridazine.Vet Approved
SulfaguanidineThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfaguanidine.Experimental
SulfaisodimidineThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfaisodimidine.Experimental
SulfamazoneThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfamazone.Experimental
SulfamerazineThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfamerazine.Approved, Vet Approved
SulfameterThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfameter.Approved
SulfamethazineThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfamethazine.Approved, Investigational, Vet Approved
SulfamethizoleThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfamethizole.Approved, Investigational, Vet Approved
SulfamethoxazoleThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfamethoxazole.Approved
SulfamethoxypyridazineThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfamethoxypyridazine.Experimental
SulfametomidineThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfametomidine.Experimental
SulfametopyrazineThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfametopyrazine.Approved, Withdrawn
SulfamoxoleThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfamoxole.Approved
SulfanilamideThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfanilamide.Approved
SulfanitranThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfanitran.Vet Approved
SulfaperinThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfaperin.Experimental
SulfaphenazoleThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfaphenazole.Approved
SulfapyridineThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfapyridine.Approved
SulfaquinoxalineThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfaquinoxaline.Vet Approved
SulfasalazineSulfasalazine may increase the hypoglycemic activities of Glipizide.Approved
SulfathiazoleThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfathiazole.Approved, Vet Approved
SulfathioureaThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfathiourea.Experimental
SulfatolamideThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfatolamide.Experimental
SulfisoxazoleThe therapeutic efficacy of Glipizide can be increased when used in combination with Sulfisoxazole.Approved, Vet Approved
SulindacThe protein binding of Glipizide can be decreased when combined with Sulindac.Approved, Investigational
SumatriptanThe therapeutic efficacy of Glipizide can be increased when used in combination with Sumatriptan.Approved, Investigational
SunitinibGlipizide may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenThe protein binding of Glipizide can be decreased when combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe protein binding of Glipizide can be decreased when combined with Suxibuzone.Experimental
TacrolimusThe therapeutic efficacy of Glipizide can be decreased when used in combination with Tacrolimus.Approved, Investigational
TalinololTalinolol may increase the hypoglycemic activities of Glipizide.Investigational
TalniflumateThe protein binding of Glipizide can be decreased when combined with Talniflumate.Approved
TaspoglutideTaspoglutide may increase the hypoglycemic activities of Glipizide.Investigational
Technetium Tc-99m ciprofloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Technetium Tc-99m ciprofloxacin.Investigational
TelaprevirThe metabolism of Glipizide can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Glipizide can be decreased when combined with Telithromycin.Approved
TemafloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Temafloxacin.Withdrawn
TemsirolimusThe therapeutic efficacy of Glipizide can be decreased when used in combination with Temsirolimus.Approved
TeneligliptinTeneligliptin may increase the hypoglycemic activities of Glipizide.Investigational
TenidapThe protein binding of Glipizide can be decreased when combined with Tenidap.Experimental
TenoxicamThe protein binding of Glipizide can be decreased when combined with Tenoxicam.Approved
TepoxalinThe protein binding of Glipizide can be decreased when combined with Tepoxalin.Vet Approved
TertatololTertatolol may increase the hypoglycemic activities of Glipizide.Experimental
TestosteroneTestosterone may increase the hypoglycemic activities of Glipizide.Approved, Investigational
Testosterone cypionateTestosterone cypionate may increase the hypoglycemic activities of Glipizide.Approved
Testosterone enanthateTestosterone enanthate may increase the hypoglycemic activities of Glipizide.Approved
Testosterone propionateThe serum concentration of Glipizide can be decreased when it is combined with Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateTestosterone undecanoate may increase the hypoglycemic activities of Glipizide.Approved, Investigational
TianeptineTianeptine may decrease the hypoglycemic activities of Glipizide.Approved, Investigational
Tiaprofenic acidThe protein binding of Glipizide can be decreased when combined with Tiaprofenic acid.Approved
TimololTimolol may increase the hypoglycemic activities of Glipizide.Approved
TinoridineThe protein binding of Glipizide can be decreased when combined with Tinoridine.Investigational
TioclomarolGlipizide may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe serum concentration of Glipizide can be decreased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Glipizide can be decreased when it is combined with Tocilizumab.Approved
TolazamideTolazamide may increase the hypoglycemic activities of Glipizide.Approved, Investigational
TolbutamideGlipizide may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidThe protein binding of Glipizide can be decreased when combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe protein binding of Glipizide can be decreased when combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypoglycemic activities of Glipizide.Approved
TorasemideThe therapeutic efficacy of Glipizide can be increased when used in combination with Torasemide.Approved
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
TrazodoneTrazodone may increase the hypoglycemic activities of Glipizide.Approved, Investigational
TriamcinoloneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TrimipramineTrimipramine may decrease the hypoglycemic activities of Glipizide.Approved
TriptorelinThe therapeutic efficacy of Glipizide can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Glipizide can be increased when used in combination with Troglitazone.Investigational, Withdrawn
Trolamine salicylateTrolamine salicylate may increase the hypoglycemic activities of Glipizide.Approved
TroleandomycinThe metabolism of Glipizide can be decreased when combined with Troleandomycin.Approved
TrovafloxacinThe therapeutic efficacy of Glipizide can be increased when used in combination with Trovafloxacin.Approved, Investigational, Withdrawn
UbidecarenoneThe therapeutic efficacy of Glipizide can be increased when used in combination with Ubidecarenone.Approved, Investigational, Nutraceutical
ValdecoxibThe protein binding of Glipizide can be decreased when combined with Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Glipizide can be decreased when combined with Valproic Acid.Approved, Investigational
VemurafenibThe serum concentration of Glipizide can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the hypoglycemic activities of Glipizide.Approved
VerapamilThe metabolism of Glipizide can be decreased when combined with Verapamil.Approved
VildagliptinVildagliptin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
VogliboseVoglibose may increase the hypoglycemic activities of Glipizide.Approved, Investigational
VoriconazoleThe serum concentration of Glipizide can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe therapeutic efficacy of Glipizide can be decreased when used in combination with Vorinostat.Approved, Investigational
WarfarinGlipizide may increase the anticoagulant activities of Warfarin.Approved
XipamideThe therapeutic efficacy of Glipizide can be increased when used in combination with Xipamide.Experimental
ZaltoprofenThe protein binding of Glipizide can be decreased when combined with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Glipizide can be decreased when it is combined with Zidovudine.Approved
ZimelidineZimelidine may increase the hypoglycemic activities of Glipizide.Withdrawn
ZiprasidoneThe therapeutic efficacy of Glipizide can be decreased when used in combination with Ziprasidone.Approved
ZomepiracThe protein binding of Glipizide can be decreased when combined with Zomepirac.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Avoid sugar and sugary food.
  • Take 30-60 minutes before breakfast.

References

Synthesis Reference

Suresh Kumar Gidwani, Purushottam Singnurkar, Prashant Kumar Tewari, "Sustained release pharmaceutical composition containing glipizide and method for producing same." U.S. Patent US6270797, issued February, 2000.

US6270797
General References
Not Available
External Links
Human Metabolome Database
HMDB0015200
KEGG Drug
D00335
PubChem Compound
3478
PubChem Substance
46505865
ChemSpider
3359
BindingDB
50012956
ChEBI
5384
ChEMBL
CHEMBL1073
Therapeutic Targets Database
DAP000920
PharmGKB
PA449762
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Glipizide
ATC Codes
A10BB07 — Glipizide
FDA label
Download (48.8 KB)
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingBasic ScienceType 2 Diabetes Mellitus1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentType 2 Diabetes Mellitus1
2CompletedTreatmentImpaired Glucose Tolerance (IGT) / Type 2 Diabetes Mellitus1
2CompletedTreatmentType 2 Diabetes Mellitus1
3CompletedTreatmentAtherosclerosis / Cardiovascular Disease (CVD) / Type 2 Diabetes Mellitus1
3CompletedTreatmentDiabetes Mellitus (DM)1
3CompletedTreatmentEnd-Stage Kidney Disease / Type 2 Diabetes Mellitus1
3CompletedTreatmentRenal Insufficiency,Chronic / Type 2 Diabetes Mellitus2
3CompletedTreatmentType 2 Diabetes Mellitus7
4CompletedTreatmentCoronary Artery Disease / Type 2 Diabetes Mellitus1
4CompletedTreatmentType 2 Diabetes Mellitus3
4Unknown StatusBasic ScienceType 2 Diabetes Mellitus1
4Unknown StatusTreatmentSevere Hyperglycemia - Blood Glucose Level >300mg/dl / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus3
Not AvailableCompletedHealth Services ResearchGenotyping / Pharmacokinetics1
Not AvailableCompletedTreatmentChronic Kidney Disease (CKD) / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Alphapharm Party Ltd.
  • Amerisource Health Services Corp.
  • Apotex Inc.
  • Apotheca Inc.
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Bristol-Myers Squibb Co.
  • Bryant Ranch Prepack
  • Caraco Pharmaceutical Labs
  • Cardinal Health
  • Coupler Enterprises Inc.
  • Dept Health Central Pharmacy
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Duramed
  • Goldline Laboratories Inc.
  • Greenstone LLC
  • Heartland Repack Services LLC
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Legacy Pharmaceuticals Packaging LLC
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Medvantx Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • Patheon Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacy Service Center
  • Pharmedix
  • Physicians Total Care Inc.
  • Pratt Pharmaceuticals
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Qualitest
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Sandoz
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Stat Scripts LLC
  • Teva Pharmaceutical Industries Ltd.
  • Torpharm Inc.
  • UDL Laboratories
  • United Research Laboratories Inc.
  • US Pharmaceutical Group
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral5 mg/1
Tablet, film coatedOral
Tablet, film coated, extended releaseOral10 mg/1
Tablet, film coated, extended releaseOral2.5 mg/1
Tablet, film coated, extended releaseOral5 mg/1
Tablet, extended releaseOral10 mg/1
Tablet, extended releaseOral2.5 mg/1
Tablet, extended releaseOral5 mg/1
Prices
Unit descriptionCostUnit
Glipizide powder36.11USD g
Glucotrol XL 10 mg 24 Hour tablet1.53USD tablet
Glucotrol xl 10 mg tablet1.37USD tablet
Metaglip 5-500 mg tablet1.33USD tablet
Metaglip 2.5-500 mg tablet1.32USD tablet
Metaglip 2.5-250 mg tablet1.2USD tablet
Glucotrol 10 mg tablet1.19USD tablet
Glucotrol XL 2.5 mg 24 Hour tablet0.99USD tablet
Glucotrol XL 5 mg 24 Hour tablet0.99USD tablet
GlipiZIDE XL 10 mg 24 Hour tablet0.84USD tablet
Glucotrol 5 mg tablet0.69USD tablet
Glucotrol xl 2.5 mg tablet0.69USD tablet
Glucotrol xl 5 mg tablet0.69USD tablet
Glipizide 10 mg tablet0.67USD tablet
GlipiZIDE XL 2.5 mg 24 Hour tablet0.63USD tablet
GlipiZIDE XL 5 mg 24 Hour tablet0.5USD tablet
Glipizide 5 mg tablet0.36USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5591454No1994-01-072014-01-07Us
US5024843No1992-09-052009-09-05Us
CA2024502No1997-11-112010-08-31Canada
USRE44459No1999-03-262019-03-26Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)200-203U.S. Patent 3,669,966.
water solubility37.2 mg/LNot Available
logP1.91HANSCH,C ET AL. (1995)
pKa5.9PANTEN,U ET AL. (1989)
Predicted Properties
PropertyValueSource
Water Solubility0.0164 mg/mLALOGPS
logP1.83ALOGPS
logP1.43ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)4.32ChemAxon
pKa (Strongest Basic)0.059ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area130.15 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity115.62 m3·mol-1ChemAxon
Polarizability47.64 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9262
Blood Brain Barrier+0.5599
Caco-2 permeable-0.7025
P-glycoprotein substrateSubstrate0.5326
P-glycoprotein inhibitor INon-inhibitor0.7469
P-glycoprotein inhibitor IINon-inhibitor0.9302
Renal organic cation transporterNon-inhibitor0.8322
CYP450 2C9 substrateSubstrate0.5731
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.719
CYP450 1A2 substrateNon-inhibitor0.9501
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.7745
CarcinogenicityNon-carcinogens0.826
BiodegradationNot ready biodegradable0.9703
Rat acute toxicity2.1662 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9118
hERG inhibition (predictor II)Non-inhibitor0.8539
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0009600000-3a2ab7e8e725ab4b2090
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-0329000000-a6f7044e9dfe397cfcdd
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0119600000-895a0f8ef34678f1200d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-1429000000-60bdb648d5355af7a75b
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0v4i-3941000000-57ab7532afaad5f9a2ac

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonamides
Direct Parent
Benzenesulfonamides
Alternative Parents
Benzenesulfonyl compounds / Sulfonylureas / Pyrazines / Organosulfonic acids and derivatives / Heteroaromatic compounds / Aminosulfonyl compounds / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
Benzenesulfonamide / Benzenesulfonyl group / Sulfonylurea / Pyrazine / Organic sulfonic acid or derivatives / Heteroaromatic compound / Aminosulfonyl compound / Sulfonyl / Organosulfonic acid or derivatives / Carboximidic acid
show 14 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyrazines, monocarboxylic acid amide, aromatic amide, N-sulfonylurea (CHEBI:5384)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sulfonylurea receptor activity
Specific Function
Subunit of the beta-cell ATP-sensitive potassium channel (KATP). Regulator of ATP-sensitive K(+) channels and insulin release.
Gene Name
ABCC8
Uniprot ID
Q09428
Uniprot Name
ATP-binding cassette sub-family C member 8
Molecular Weight
176990.36 Da
References
  1. Gribble FM, Ashcroft FM: Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism. 2000 Oct;49(10 Suppl 2):3-6. [PubMed:11078468]
  2. Harrower A: Gliclazide modified release: from once-daily administration to 24-hour blood glucose control. Metabolism. 2000 Oct;49(10 Suppl 2):7-11. [PubMed:11078469]
  3. Lawrence CL, Proks P, Rodrigo GC, Jones P, Hayabuchi Y, Standen NB, Ashcroft FM: Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia. 2001 Aug;44(8):1019-25. [PubMed:11484080]
  4. Reimann F, Ashcroft FM, Gribble FM: Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9. [PubMed:11574406]
  5. Proks P, Reimann F, Green N, Gribble F, Ashcroft F: Sulfonylurea stimulation of insulin secretion. Diabetes. 2002 Dec;51 Suppl 3:S368-76. [PubMed:12475777]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Scarsi M, Podvinec M, Roth A, Hug H, Kersten S, Albrecht H, Schwede T, Meyer UA, Rucker C: Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. Mol Pharmacol. 2007 Feb;71(2):398-406. Epub 2006 Nov 2. [PubMed:17082235]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Details
2. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. doi: 10.1124/dmd.104.000794. Epub 2004 Aug 10. [PubMed:15304429]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 12:55